LIO ASQELIO TM monofocal QLIO130C: Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
Study summary
The goal of this observational study is to learn about the Asqelio monofocal intraocular lens (IOL) model QLIO130C in patients undergoing cataract surgery. The aim of the study is to evaluate the lens implementation safety and efficacy after at least 24 months.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Subjects 22 years of age or older undergoing cataract surgery in at least 1 eye and implanted with ASQELIO monofocal model QLIO130C.
* Subjects for whom postoperative emmetropia (±0.5 D spherical equivalent) was planned.
Exclusion Criteria:
* Any pathology that reduces the potential Visual Acuity (VA) with its best correction beyond 0.30 logMAR.
* Previous corneal surgery.
* Rubella or surgery due to traumatic cataract.
* Ocular trauma or refractive surgery.
* Any other ocular or systemic condition that, in the opinion of the investigator, should exclude the subject from the study
Primary outcome measure(s)
Incidence of Posterior capsular opacity — 24 months after IOL implantation Incidence of PCO
Intensity of Posterior capsular opacity — 24 months after IOL implantation Intensity of PCO determined using LOCSIII Classification
Visual acuity — At least 24 months after IOL implantation Best corrected distance visual acuity in LogMAR units using the ETDRS chart
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
